Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension
SL Archer, ED Michelakis - New England Journal of Medicine, 2009 - Mass Medical Soc
New England Journal of Medicine, 2009•Mass Medical Soc
A 46-year-old-woman presents with exertional dyspnea and syncope and receives a
diagnosis of idiopathic pulmonary arterial hypertension. Treatment with sildenafil is
recommended. Sildenafil and tadalafil are phosphodiesterase type 5 inhibitors that
ameliorate pulmonary arterial hypertension by increasing levels of cyclic guanosine
monophosphate in the smooth-muscle cells of the pulmonary artery.
diagnosis of idiopathic pulmonary arterial hypertension. Treatment with sildenafil is
recommended. Sildenafil and tadalafil are phosphodiesterase type 5 inhibitors that
ameliorate pulmonary arterial hypertension by increasing levels of cyclic guanosine
monophosphate in the smooth-muscle cells of the pulmonary artery.
A 46-year-old-woman presents with exertional dyspnea and syncope and receives a diagnosis of idiopathic pulmonary arterial hypertension. Treatment with sildenafil is recommended. Sildenafil and tadalafil are phosphodiesterase type 5 inhibitors that ameliorate pulmonary arterial hypertension by increasing levels of cyclic guanosine monophosphate in the smooth-muscle cells of the pulmonary artery.
The New England Journal Of Medicine